Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.217320 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Letters, 2024. Verfasst von Julianna Korns und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, …. Hauptthemen laut MEDLINE: Cisplatin, Radiation-Sensitizing Agents, Head and Neck Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: BLRD VA, NCI NIH HHS, NIDCR NIH HHS.
Abstract (Originalsprache)
The efficacy of radiation treatment (RT) of head and neck squamous cell carcinoma (HNSCC) is limited by radioresistance and the toxicity of FDA approved radiosensitizers. In extension to our previous research where we demonstrated that telaglenastat (CB839) increased efficacy of RT in in vitro and in vivo HNSCC models, here, we examine the radiosensitizing effects of telaglenastat in comparison to cisplatin's, as cisplatin is currently the standard of care for concurrent therapy. Combination of telaglenastat with RT reduced tumor volume in a HNSCC patient derived xenograft mouse model. The efficacy of telaglenastat with RT in reducing cell survival and increasing apoptosis was similar if not greater than that of cisplatin with RT in Cal27 and HN5 HNSCC cells. The addition of telaglenastat increased reactive oxygen species and reduced the antioxidant glutathione in both Cal27 and HN5 cells. Reverse Phase Protein Array analyses revealed alterations in cell death and DNA damage response proteins. This study provides the scientific underpinnings for the use of telaglenastat as a radiosensitizer in the treatment of HNSCC either as an alternative to cisplatin or in cisplatin-ineligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA; Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA.
- Department of Radiation Oncology, University of Cincinnati, Cincinnati, OH, USA.
- Cincinnati Medicine, University of Cincinnati, Cincinnati, OH, USA.
- Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA.
- Department of Internal Medicine, Division of Hematology Oncology, University of Cincinnati, Cincinnati, OH, USA.
- Department of Cancer Biology, University of Cincinnati, Cincinnati, OH, USA; Research Service, Cincinnati Veteran's Affairs Medical Center, Cincinnati, OH, USA.
Förderung
- BLRD VA
- NCI NIH HHS
- NIDCR NIH HHS
- NIEHS NIH HHS
- U.S. Department of Veterans Affairs
- National Institute of Dental and Craniofacial Research
- US Department of Energy
- National Cancer Institute
Zitieren
APA
Korns, J., Wicker, C. A., Lehn, M., Shyamsunder, S., Thompson, S., Lester, C., Wise-Draper, T. M., Waltz, S. E., & Takiar, V. (2024). Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.217320
Vancouver
Korns J, Wicker CA, Lehn M, Shyamsunder S, Thompson S, Lester C, et al. Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.217320
BibTeX
@article{Korns2024,
author = {Korns, Julianna and Wicker, Christina A and Lehn, Maria and Shyamsunder, Shreya and Thompson, Samuel and Lester, Carissa and Wise-Draper, Trisha M and Waltz, Susan E and Takiar, Vinita},
title = {Telaglenastat as an alternative to cisplatin as a radiosensitizer in the treatment of head and neck squamous cell carcinoma},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.217320}
}
EUVIMED